Product
Best Available Treatment
1 clinical trial
6 indications
Indication
Urinary Tract InfectionIndication
PyelonephritisIndication
Hospital-Acquired PneumoniaIndication
Ventilator-associated pneumoniaIndication
BacteremiaIndication
Intra-abdominal infectionClinical trial
AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED STUDY TO ESTIMATE THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) VERSUS BEST AVAILABLE TREATMENT (BAT) IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT GRAM-NEGATIVE PATHOGENS IN CHINESE ADULTSStatus: Completed, Estimated PCD: 2023-08-31